DK2452189T3 - Fremgangsmåde til identifikation af forbindelser til behandling af cancer - Google Patents

Fremgangsmåde til identifikation af forbindelser til behandling af cancer

Info

Publication number
DK2452189T3
DK2452189T3 DK10730456.0T DK10730456T DK2452189T3 DK 2452189 T3 DK2452189 T3 DK 2452189T3 DK 10730456 T DK10730456 T DK 10730456T DK 2452189 T3 DK2452189 T3 DK 2452189T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
identifying compounds
identifying
compounds
Prior art date
Application number
DK10730456.0T
Other languages
English (en)
Inventor
Gonzalez Maria Soledad Soengas
Carulla Damia Tormo
Original Assignee
Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii filed Critical Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii
Application granted granted Critical
Publication of DK2452189T3 publication Critical patent/DK2452189T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
DK10730456.0T 2009-07-04 2010-07-05 Fremgangsmåde til identifikation af forbindelser til behandling af cancer DK2452189T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930417A ES2368963B1 (es) 2009-07-04 2009-07-04 Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
PCT/EP2010/059593 WO2011003883A1 (en) 2009-07-04 2010-07-05 Process for the identification of compounds for treating cancer

Publications (1)

Publication Number Publication Date
DK2452189T3 true DK2452189T3 (da) 2014-01-20

Family

ID=42556459

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10730456.0T DK2452189T3 (da) 2009-07-04 2010-07-05 Fremgangsmåde til identifikation af forbindelser til behandling af cancer

Country Status (18)

Country Link
US (5) US20120172581A1 (da)
EP (1) EP2452189B1 (da)
JP (2) JP5908398B2 (da)
KR (1) KR101877840B1 (da)
CN (3) CN104857016B (da)
AU (1) AU2010270291B2 (da)
BR (1) BR112012000098B1 (da)
CA (1) CA2767148C (da)
DK (1) DK2452189T3 (da)
ES (2) ES2368963B1 (da)
IL (1) IL217310A (da)
MX (1) MX2012000280A (da)
NZ (1) NZ597793A (da)
PL (1) PL2452189T3 (da)
PT (1) PT2452189E (da)
SG (1) SG177482A1 (da)
WO (1) WO2011003883A1 (da)
ZA (1) ZA201200116B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572820B2 (en) 2011-05-10 2017-02-21 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
KR102589295B1 (ko) 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
EP3319587B1 (en) * 2015-11-17 2019-08-21 Bioncotech Therapeutics, S.L Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN114632091A (zh) * 2016-04-01 2022-06-17 依生生物制药(新加坡)私人有限公司 用于治疗癌症的含有聚核苷酸的药物组合物
US10849921B2 (en) 2017-05-17 2020-12-01 Bioncotech Therapeutics Sl Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
CN109200056A (zh) * 2018-11-20 2019-01-15 苏州系统医学研究所 聚肌胞在防治胰腺炎及其相关病症中的用途
WO2020104628A1 (en) 2018-11-21 2020-05-28 Bioncotech Therapeutics S.L Nanoplexed poly(i:c) formulations and uses thereof
US12287338B2 (en) * 2019-11-27 2025-04-29 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
CN111166769B (zh) * 2020-03-18 2022-01-11 山东大学 真皮成纤维细胞在治疗黑色素瘤中的应用
CA3182874A1 (en) * 2020-06-15 2021-12-23 Karina BETTEGA FELIPE Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and chemotherapy agents
WO2022111829A1 (en) 2020-11-30 2022-06-02 Symrise Ag Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes
CN113413460A (zh) * 2021-08-10 2021-09-21 中山大学·深圳 Traf6抑制剂在制备黑色素瘤药物中的应用
KR102747085B1 (ko) * 2022-09-16 2024-12-27 재단법인 아산사회복지재단 자가포식 조절제를 스크리닝하는 방법
WO2025202219A1 (en) * 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Mda5 inhibition as a broad defense and healthspan extending strategy
CN119925643A (zh) * 2025-01-23 2025-05-06 中国科学院生物物理研究所 提高lsh含量或活性的物质在提高异染色质稳定性与增强细胞治疗疗效中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124702A (en) * 1971-07-06 1978-11-07 Merck & Co., Inc. Polynucleotides active as inducers of interferon production in living animal cells
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
US7229822B1 (en) * 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
EP1476199A2 (en) * 2002-02-14 2004-11-17 Research Development Foundation Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
US7927792B2 (en) * 2002-11-18 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Targeted double stranded RNA mediated cell killing
CA2548992A1 (en) * 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
US20080220416A1 (en) * 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
CA2567526A1 (en) * 2004-05-26 2005-12-15 Wisconsin Alumni Research Foundation Cancer treatment method by inhibiting mage gene expression or function
WO2006119619A1 (en) * 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
CN101182517A (zh) * 2007-12-18 2008-05-21 广州拓谱基因技术有限公司 用于疾病治疗的多靶点鸡尾酒双链小干扰rna及其制备方法

Also Published As

Publication number Publication date
WO2011003883A1 (en) 2011-01-13
EP2452189B1 (en) 2013-10-16
CN104857016B (zh) 2019-12-24
JP6222749B2 (ja) 2017-11-01
CN102483404A (zh) 2012-05-30
IL217310A0 (en) 2012-02-29
US20170020917A1 (en) 2017-01-26
EP2452189A1 (en) 2012-05-16
JP2016104744A (ja) 2016-06-09
SG177482A1 (en) 2012-02-28
US20140154202A1 (en) 2014-06-05
ES2368963B1 (es) 2012-10-10
US20120172581A1 (en) 2012-07-05
ES2368963A1 (es) 2011-11-24
JP5908398B2 (ja) 2016-04-26
CN110974842B (zh) 2023-09-19
ZA201200116B (en) 2012-09-26
CN110974842A (zh) 2020-04-10
AU2010270291B2 (en) 2014-10-09
NZ597793A (en) 2013-05-31
RU2012103902A (ru) 2013-08-20
PT2452189E (pt) 2014-01-22
US20190134077A1 (en) 2019-05-09
AU2010270291A1 (en) 2012-02-16
IL217310A (en) 2017-05-29
KR101877840B1 (ko) 2018-08-09
PL2452189T3 (pl) 2014-05-30
ES2442623T3 (es) 2014-02-12
JP2012531193A (ja) 2012-12-10
BR112012000098A2 (pt) 2014-10-07
CA2767148A1 (en) 2011-01-13
KR20120055550A (ko) 2012-05-31
MX2012000280A (es) 2012-12-05
US20190117685A1 (en) 2019-04-25
CA2767148C (en) 2019-05-28
CN104857016A (zh) 2015-08-26
BR112012000098B1 (pt) 2019-03-06

Similar Documents

Publication Publication Date Title
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
DK2325648T3 (da) Fremgangsmåde til detektering af cancer
DK2440545T3 (da) Forbindelser, der er anvendelige til behandling af cancer
BRPI0810206A2 (pt) Método de tratar câncer
DK2504451T3 (da) Fremgangsmåder til at forudsige det kliniske forløb af cancer
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
IL232222A0 (en) Methods for treating progressive multiple sclerosis
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
BRPI1013317A2 (pt) método de cimentação
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
DK3106873T3 (da) Fremgangsmåde til detektering af cancer
LT2313364T (lt) Simetrinio dimetilarginino nustatymo būdai
DK3276004T3 (da) Fremgangsmåder til behandling af kronisk nyresygdom
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
HUE052219T2 (hu) Eljárás kinolon vegyületek elõállítására
IL226246A0 (en) Methods of treating cancer
BR112014011008A2 (pt) método de quantificação de tratamento de câncer